Peter Attia· MD
the spike the top of the spike is the peak level the bottom before you take the nectar next dose is the trough
Loading…
The headline is broadly defensible, but the qualifications matter. Effect sizes vary by population, the strongest claims rest on shorter trials, and credible voices push back on how it's typically framed.
the spike the top of the spike is the peak level the bottom before you take the nectar next dose is the trough
Every Sunday: the week’s new conflicts and verdict changes — and nothing else.
Native comments, Twitter mentions, and Reddit threads about this claim — surfaced together so the conversation isn't fragmented across platforms.
The "high risk" framing here is the right call. I've had three patients ask about rapa this month and none of them grasped the immunosuppression tradeoff until I walked them through it.
The PEARL trial framing in the dossier is the clearest writeup I've seen for a non-specialist. Worth linking from the AMA pages too.
I'm on 6mg/week, year two. Tracking IL-6, fasting glucose, lipids. Happy to share the spreadsheet if Whalespan wants longitudinal user data.
The dosing variance across the advocate camp is staggering. 3mg, 5mg, 8mg, biweekly, weekly… brief is right that "monitor or specialist only" is the responsible read.
so I kind of think that's probably true but I'm not confident and I really think we need more data to know for sure it's certainly true in other classes of drugs and when you look at gentamicin for example in the auto toxicity or nephrotoxicity it's a trough problem not a peak problem right yeah so what do I have to make sure the patient's clear it before you read those so there's there are other reasons to believe that you know yeah
because the side effects are driven by the trough levels as well as the efficacy and i think that's also true with gentamicin and a lot of the negative the antibiotics that have the same toxicities on the trough right yes
Rapamycin extends median and maximum lifespan in mice across multiple lab strains and dosing protocols.
Rapamycin will extend human lifespan by 5+ years at standard weekly dosing.
Weekly rapamycin dosing in healthy adults shows favorable safety and immune markers in early observational data.
Chronic low-dose rapamycin imposes an immune trade-off that outweighs the longevity hypothesis for most healthy adults.
mTORC1 inhibition is the mechanistic backbone for rapamycin's healthspan effects in mammals.
The PEARL trial showed an acceptable 48-week safety profile in healthy adults on weekly rapamycin.